Venture capital fund · 1 deal
Every published round Arboretum Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Allay Therapeutics | Series C | 16 Sep 2021 | $60m | Lead | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Arboretum Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Allay Therapeutics | 16 Sep 2021, Series C | 1 | 1 |
Fund closes reported for Arboretum Ventures, as distinct from the investments it has made.
Companies Arboretum Ventures has backed that another company then bought. An exit for the holding, not a deal Arboretum Ventures did.
| Name | Role | Sources |
|---|---|---|
| Nicole J. Walker | Managing Partner | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Arboretum Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
US-Singapore biotech Allay Therapeutics has closed a $60 million Series C round led by Arboretum Ventures, with several healthcare investors taking part, to advance its long-acting post-surgical pain candidate into late-stage trials.